We may be in the early stages of a medical revolution, a revolution which changes the way in which medical professionals view and treat numerous ailments. As the fields of robotics, 3D printing, and biological research converge, 3D bioprinting is no longer a technology of the far future, but instead it’s a technology of today. There are already several pharmaceutical companies utilizing Organovo’s ExVive3D bioprinted human liver tissue for drug toxicity testing, and new companies such as BioBots are breaking onto the scene with their own bioprinting approaches. As funding continues to pour into this space, progress will naturally follow.
Today we got word from Rokit, a market leader in the 3D printing space within South Korean, that they too are entering the 3D bioprinting space with a bang. The company has today announced a $3 million government grant for the development of bioprinting technology. The project, which will include the Korean Institute of Science and Technology (KIST), Seoul National University Bundang Hospital, Hanyang University, and Korea Institute of Machinery and Materials (KIMM), is scheduled to be completed in three years, resulting in the development of an in-situ 3D bioprinter.
Rokit, known for their line of 3Dison desktop 3D printers, including the H700, Pro, Multi, AEP, S and Chocosketch models, has forged a path to success within the space over the last couple of years, particularly in the continent of Asia, and now looks to expand to what may eventually be a multi-billion dollar opportunity.
The company appears to be focusing initially on the bioprinting of human skin tissue, a technology which could change the way patients are treated for a variety of ailments from burns to diseases, to even cosmetic surgery.
“Traditional Autografts and commercially available skin products are limited in supply and it’s common for production to require lengthy preparation time, making them unusable in severe cases which require prompt usage,” explained the company. “In addition to this production issue, transplantation involves a number of biological side-effects which cause patients to take other surgeries to relieve side effects. Bio-printing technology effectively resolves such problems in transplantation and South Korea Government now jumped into the market with the most promising company in 3D printers industry, Rokit.”
Rokit will join a handful of companies now in the early stages of bioprinting research who have received major funding lately. Organovo raised $40 million last month in a secondary stock offering, while BioBots has raised over $300,000 on crowdfunding platform Fundable for further development on their desktop bioprinters. It’s certainly going to be an exciting space to watch over the next 2-3 years as the technology matures.
Let us know your thoughts on this move by Rokit to enter the 3D bioprinting space, and what it may mean for the industry as a whole. Discuss in the Rokit Bioprinting forum thread on 3DPB.com.
You May Also Like
Nexa3D Acquires NXT Factory, Introduces Eco-Friendly 3D Printing Washing Solvent
While Nexa3D may specialize in manufacturing super-fast stereolithography 3D printers, the company has been branching out recently, and narrowing its focus on the materials side of things. It launched the...
DyeMansion Secures Additional $14M in Series B Funding from New & Existing Investors
German company DyeMansion is known for its coloring and post-processing equipment, such as its three-step Print-to-Product workflow geared toward industrial 3D printing environments. Now, in order to continue transforming and...
T3D Announces New LCD-Based High-Speed 3D Printing System
Taiwan 3D Tech, also known as T3D, is a startup spin-off from the National Taiwan University of Science and Technology (NTUST). Headquartered in Taipei, the company was officially founded in...
3DPOD Episode 32: Tuan TranPham, Arevo
Tuan is known universally by his first name alone. Like Madonna and Beyonce, everyone knows hi by just that one name. In Tuan’s case his fame is 3D printing specific...
View our broad assortment of in house and third party products.